Integrated Filing — IndAS


General information about company

Scrip Code 533138
NSE Symbol ASTEC
MSEI Symbol NOTLISTED
ISIN INE563J01010
Name of company ASTEC LIFESCIENCES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 23-Apr-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 15-Apr-2025
Description of presentation currency INR (in Actuals)
Reporting Type Half Yearly
Reporting Quarter Yearly
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment AGROCHEMICALS
Start date and time of board meeting 23-Apr-2025   15:15:00
End date and time of board meeting 23-Apr-2025   17:20:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2024-10-25
Indicate Company website link for updated RPT policy of the Company https://www.godrejastec.com/investors/codes-and-policies
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No Default



Financial Results Ind-AS

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Oct-2024 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 2133854000 3813035000
Other income 26692000 55581000
Total income 2160546000 3868616000
2 Expenses
(a) Cost of materials consumed 1487648000 2488599000
(b) Purchases of stock-in-trade 0 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -136461000 480763000
(d) Employee benefit expense 299416000 611045000
(e) Finance costs 203245000 367070000
(f) Depreciation, depletion and amortisation expense 230083000 437740000
(f) Other Expenses
1 Power and fuel 485389000 894581000
Total other expenses 485389000 894581000
Total expenses 2569320000 5279798000
3 Total profit before exceptional items and tax -408774000 -1411182000
4 Exceptional items 0 0
5 Total profit before tax -408774000 -1411182000
6 Tax expense
7 Current tax 0 0
8 Deferred tax 156211000 -63100000
9 Total tax expenses 156211000 -63100000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations -564985000 -1348082000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period -564985000 -1348082000
17 Other comprehensive income net of taxes -2364000 1688000
18 Total Comprehensive Income for the period -567349000 -1346394000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 0 0
Face value of equity share capital 0 0
27 Details of debt securities
22 Reserves excluding revaluation reserve 0
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -28.81 -68.74
Diluted earnings (loss) per share from continuing operations -28.81 -68.74
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -28.81 -68.74
Diluted earnings (loss) per share from continuing and discontinued operations -28.81 -68.74
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 4963336000
Capital work-in-progress 1251000
Investment property 0
Goodwill 0
Other intangible assets 22010000
Intangible assets under development 212475000
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 4271000
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 13629000
Total non-current financial assets 17900000
Deferred tax assets (net) 0
Other non-current assets 187601000
Total non-current assets 5404573000
2 Current assets
Inventories 1598107000
Current financial asset
Current investments 0
Trade receivables, current 1474427000
Cash and cash equivalents 5650000
Bank balance other than cash and cash equivalents 9324000
Loans, current 27718000
Other current financial assets 6418000
Total current financial assets 1523537000
Current tax assets (net) 0
Other current assets 277959000
Total current assets 3399603000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 8804176000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 196114000
Other equity 2144625000
Total equity attributable to owners of parent 2340739000
Non controlling interest
Total equity 2340739000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 2800000000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 2900000
Total non-current financial liabilities 2802900000
Provisions, non-current 3667000
Deferred tax liabilities (net) 0
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 2806567000
Current liabilities
Current financial liabilities
Borrowings, current 2745441000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 41363000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 774539000
Total Trade payable 815902000
Other current financial liabilities 68441000
Total current financial liabilities 3629784000
Other current liabilities 17306000
Provisions, current 9780000
Current tax liabilities (Net) 0
Deferred government grants, Current 0
Total current liabilities 3656870000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 6463437000
Total equity and liabilites 8804176000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Oct-2024 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Oct-2024 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of defined benefit liability -1796000 2256000
Total Amount of items that will not be reclassified to profit and loss -1796000 2256000
2 Income tax relating to items that will not be reclassified to profit or loss 568000 568000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income -2364000 1688000



Cash flow statement, indirect

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 2024-04-01
B Date of end of reporting period 2025-03-31
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax -1411182000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 367070000
Adjustments for decrease (increase) in inventories 158678000
Adjustments for decrease (increase) in trade receivables, current 188834000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets 14340000
Adjustments for decrease (increase) in other non-current assets 1700000
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current -10373000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current -77938000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 4320000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 437740000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current -2307000
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 5193000
Adjustments for other financial liabilities, non-current -17600000
Adjustments for unrealised foreign exchange losses gains 32317000
Adjustments for dividend income 0
Adjustments for interest income 7326000
Adjustments for share-based payments 345000
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow -20181000
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 202156000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 1276968000
Net cash flows from (used in) operations -134214000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) -50314000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities -83900000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 0
Purchase of property, plant and equipment 218222000
Proceeds from sales of investment property 59679000
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 7224000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 19000
Net cash flows from (used in) investing activities -151300000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 23000
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 1710000000
Repayments of borrowings 1087155000
Payments of lease liabilities 977000
Dividends paid 0
Interest paid 385646000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities 236245000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 1045000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 1045000
Cash and cash equivalents cash flow statement at beginning of period 4605000
Cash and cash equivalents cash flow statement at end of period 5650000







Details of Impact of Audit Qualification

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 BSR & Co. LLP Yes 31-Jul-2025


Financial details

Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth




Signatories detail

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date



Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Astec Lifesciences Limited Godrej Agrovet Limited Holding Company Sale of goods or services Requisite approval taken 9290000 9622000 11438000
2 Astec Lifesciences Limited Godrej Agrovet Limited Holding Company Purchase of goods or services Requisite approval taken 206076000 11336000 216645000
3 Astec Lifesciences Limited Godrej & Boyce Manufacturing Company Limited Group Company Purchase of fixed assets Requisite approval taken 248000 0 0
4 Astec Lifesciences Limited Godrej Agrovet Limited Holding Company Any other transaction Expenses Charged by / Reimbursement made to other companies Requisite approval taken 25551000 0 39000
5 Astec Lifesciences Limited Godrej Industries Limited Ultimate Holding Company Any other transaction Expenses Charged by / Reimbursement made to other companies Requisite approval taken 563000 0 0
6 Astec Lifesciences Limited Godrej Consumer Products Limited Group Company Any other transaction Expenses Charged by / Reimbursement made to other companies/related parties Requisite approval taken 803000 0 0
7 Astec Lifesciences Limited Godrej Agrovet Limited Holding company Any other transaction Expenses Charged to / Reimbursement made by other companies Requisite approval taken 38981000 0 0
8 Astec Lifesciences Limited Godrej Consumer Products Limited Group Company Any other transaction Expenses Charged to / Reimbursement made by other companies Requisite approval taken 5900000 0 983000
9 Astec Lifesciences Limited Behram Chemicals Private Limited Subsidiary Company Any other transaction Expenses Charged to / Reimbursement made by other companies Requisite approval taken 540000 439000 176000
10 Astec Lifesciences Limited Godrej Agrovet Limited Holding Company Inter-corporate deposit Requisite approval taken 380000000 655000000 290000000 Any other Inter Company Deposit 0.085 3 Years Inter-corporate deposit 0.085 3Years Unsecured General Corporate purpose
11 Astec Lifesciences Limited Godrej Agrovet Limited Holding Company Interest paid Requisite approval taken 28724000 0 0
12 Astec Lifesciences Limited Cream Line Dairy Products Limited Group Company Inter-corporate deposit Requisite approval taken 100000000 0 100023000 Any other Inter Company Deposit 0.085 8 to 180 Days Inter-corporate deposit 0.085 8 to 180 Days Unsecured General Corporate purpose
13 Astec Lifesciences Limited Cream Line Dairy Products Limited Group Company Interest paid Requisite approval taken 442000 0 0
14 Astec Lifesciences Limited Godrej Foods Limtied (formerly known as Godrej Tyson Foods Limited) Group Company Inter-corporate deposit Requisite approval taken 100000000 0 100023000 Any other Inter Company Deposit 0.085 3 Years Inter-corporate deposit 0.085 3 Years Unsecured General corporate pupose
15 Astec Lifesciences Limited Godrej Foods Limtied (formerly known as Godrej Tyson Foods Limited) Group Company Interest paid Requisite approval taken 268000 0 0
16 Astec Lifesciences Limited Comercializadora Agricola Agroastrachem Ltd Subsidiary Company Advance No transactions Requisite approval taken 0 327000 327000
17 Astec Lifesciences Limited Rishinaradamangalam Ramakrishna Director Any other transaction Director sitting fees/Travelling for Board and Committee Requisite approval taken 700000 0 0
18 Astec Lifesciences Limited Anjali Rajesh Gupte Director Any other transaction Director sitting fees/Travelling for Board and Committee Requisite approval taken 500000 0 0
19 Astec Lifesciences Limited Nandkumar Dhekne Director Any other transaction Director sitting fees/Travelling for Board and Committee Requisite approval taken 350000 0 0
20 Astec Lifesciences Limited G.D.Yadav Director Any other transaction Director sitting fees/Travelling for Board and Committee Requisite approval taken 300000 0 0
21 Astec Lifesciences Limited Astec Lifesciences Group Gratuity Trust Post employment Benefit Plan Any other transaction Contribution to post employement benefit plans Requisite approval taken 98000 0 0
22 Astec Lifesciences Limited Anurag Roy Key Management Personnel Remuneration Requisite approval taken 2818000 0 0
23 Astec Lifesciences Limited Tejashree Pradhan Key Management Personnel Remuneration Requisite approval taken 1172000 0 0
24 Astec Lifesciences Limited Mugdha Khare Key Management Personnel Remuneration Requisite approval taken 2075000 0 0
25 Astec Lifesciences Limited Arijit Mukherjee Key Management Personnel Remuneration Requisite approval taken 2510000 0 0
Total value of transaction during the reporting period 907909000





Format for Disclosing Outstanding Default on Loans and Debt Securities

Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
3. Total financial indebtedness of the listed entity including short-term and long-term debt